Overview
- Moderna and Merck announced on Friday that their personalized neoantigen vaccine, intismeran autogene, given with pembrolizumab reduced the risk of recurrence or death by about 49% and the risk of distant metastasis or death by about 59% versus pembrolizumab alone in an interim Phase 3 analysis.
- The result is an interim topline readout and the companies have not released full datasets or detailed safety tables, so investigators and outside experts are calling for longer follow-up and overall survival data before changing clinical practice.
- The therapy is bespoke: doctors sequence a patient’s tumor to pick neoantigen mutations and then manufacture a custom mRNA dose to train the immune system to target those mutations.
- Manufacturing and access questions remain unresolved because Moderna and Merck say the vaccine can be made in about six weeks but independent estimates put the process at two to four months, which affects cost, insurance coverage and timely treatment for patients.
- The positive Phase 3 signal sent shares higher and positions the partners to present full data to regulators and at medical meetings, but real-world use will depend on regulatory review, long-term benefit, scaled production and payer decisions.